Retatrutide, perhaps the most promising of the obesity medications now in the pipeline, activates GLP-1, GIP, and glucagon receptors
More States and Insurers Follow Suit The move by BCBS MI and the NC State Health Plan is part of a broader trend that can be seen everywhere: Massachusetts : BCBS MA ended GLP1 coverage for obesity effective January 1, 2025
We work hand-in-hand with your doctor to act as an extension of their practice, providing a white glove, concierge level of support that puts your health and well-being first
Instead of forcing your body into extremes, these treatments work with your biology to regulate appetite, improve insulin response, and support sustainable fat loss over time
Working Out Consistently This one hits home